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Abstract
Objectives: To evaluate whether (1) the absolute magnitude of liver 
function test values, (2) the percentage change in liver function 
test values over time, or (3) the rate of change in liver function test 
values over time predicts adverse maternal outcomes in women 
with preeclampsia
Methods: We used data from the PIERS (Pre-eclampsia Integrated 
Estimate of RiSk) study, a prospective multicentre cohort study 
assessing predictors of adverse maternal outcomes in women 
with preeclampsia Women with at least one liver function test 
performed at the time of hospital admission were included Liver 
functions were tested by serum concentrations of aspartate 
amino transferase (AST), alanine amino transferase (ALT), 
lactate dehydrogenase (LDH), albumin, total bilirubin, and the 
international normalized prothrombin time ratio Parameters 
investigated were absolute levels, change within 48 hours 
of hospital admission, change from admission to delivery or 
outcome, and rate of change from admission to delivery or 
outcome of each liver function test The ability of these parameters 
to predict adverse outcomes was assessed using logistic 
regression analyses and by calculating the receiver operating 
characteristic (ROC) area under the curve (AUC)
Results: Of the 2008 women, 1056 (53%) had at least one abnormal 
liver function test result The odds of having an adverse maternal 
outcome were higher in women with any abnormal liver function test 
than in women with normal results When test results were stratied 
into quartiles, women with results in the highest quartile (lowest 
quartile for albumin) were at higher risk of adverse outcomes 
than women in the lowest quartile for all parameters (highest for 
albumin) The absolute magnitude of AST, ALT, and LDH predicted 
adverse maternal outcomes (AST: ROC AUC 073 [95% CI 097 to 
079]; ALT: ROC AUC 073 [95% CI 067 to 079]; LDH: ROC AUC 
074 [95% CI 068 to 081]) Neither change of liver function test 
results, within 48 hours of admission or from admission to delivery 
or outcome, nor rate of change were predictive
Conclusion: We found abnormal liver function test results to be 
associated with an increased risk for adverse maternal outcomes
Levels of AST, ALT, and LDH were found to be modestly predictive 
of these outcomes
Résumé
Objectifs : Évaluer si (1) l’ampleur absolue des valeurs d’épreuve de 
fonction hépatique, (2) la modication du pourcentage des valeurs 
d’épreuve de fonction hépatique avec le temps ou (3) le taux de 
modication des valeurs d’épreuve de fonction hépatique avec le 
temps permet de prédire les issues maternelles indésirables chez 
les femmes qui présentent une prééclampsie
Méthodes : Nous avons utilisé des données issues de l’étude PIERS 
(Pre-eclampsia Integrated Estimate of RiSk), soit une étude de 
cohorte multicentrique prospective évaluant les facteurs prédictifs 
des issues maternelles indésirables chez les femmes qui 
présentent une prééclampsie Les femmes ayant subi au moins 
une épreuve de fonction hépatique au moment de l’hospitalisation 
ont été admises à l’étude Les fonctions hépatiques ont été 
testées au moyen des concentrations sériques d’aspartate 
aminotransférase (AST), d’alanine aminotransférase (ALT), de 
lactate-déshydrogénase (LDH), d’albumine, de bilirubine totale, 
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ainsi qu’au moyen du rapport international normalisé du temps de 
prothrombine Parmi les paramètres étudiés, on trouvait les taux 
absolus, la modication dans les 48 heures de l’hospitalisation, la 
modication entre l’hospitalisation et l’accouchement ou l’issue et 
le taux de modication entre l’hospitalisation et l’accouchement 
ou l’issue de chacune des épreuves de fonction hépatique La 
capacité de ces paramètres de prédire les issues indésirables 
a été évaluée au moyen d’analyses de régression logistique 
et en calculant la surface sous la courbe (SSC) de la fonction 
d’efcacité de l’observateur (FEO)
Résultats : Chez 2 008 femmes, 1 056 (53 %) avaient obtenu au 
moins un résultat anormal d’épreuve de fonction hépatique La 
probabilité de connaître une issue maternelle indésirable était 
plus élevée chez les femmes ayant obtenu un ou des résultats 
anormaux d’épreuve de fonction hépatique que chez les femmes 
ayant obtenu des résultats normaux Lorsque les résultats 
d’épreuve ont été stratiés en quartiles, les femmes dont les 
résultats se situaient dans le quartile le plus élevé (quartile le 
plus faible pour ce qui est de l’albumine) étaient exposées à des 
risques d’issues indésirables plus élevés que ceux auxquels étaient 
exposées les femmes dont les résultats se situaient dans le quartile 
le plus faible pour tous les paramètres (le plus élevé pour ce qui est 
de l’albumine) L’ampleur absolue de l’AST, de l’ALT et du LDH a 
permis de prédire les issues maternelles indésirables (AST : SSC 
FEO, 0,73 [IC à 95 %, 0,97 – 0,79]; ALT : SSC FEO, 0,73 [IC à 
95 %, 0,67 – 0,79]; LDH : SSC FEO, 0,74 [IC à 95 %, 0,68 – 0,81])
Ni la modication des résultats d’épreuve de fonction hépatique 
(dans les 48 heures de l’hospitalisation ou entre l’hospitalisation 
et l’accouchement ou l’issue) ni le taux de modication ne se sont 
avérés être des facteurs prédictifs
Conclusion : Nous avons constaté que les résultats anormaux 
d’épreuve de fonction hépatique étaient associés à un risque 
accru d’issues maternelles indésirables Nous avons également 
constaté que les taux d’AST, d’ALT et de LDH constituaient de 
modestes facteurs prédictifs quant à ces issues
INTRODUCTION
Preeclampsia is a multisystem disease that has substantial adverse effects for pregnant women and their fetuses, 
and it is a major cause of  maternal morbidity and mortality 
worldwide.1 Obstetrical organizations have produced 
guidelines to assist in its diagnosis and management.2–5 As 
the clinical presentation of  preeclampsia is variable, we 
cannot currently identify the women who will go on to 
develop severe disease and those who will have only mild 
effects. Therefore, the management of  preeclampsia is 
initially similar for all women and can be individualized only 
as their disease progresses. Being able to determine which 
women and fetuses are most at risk early in the course 
of  the illness would enable clinicians to tailor individual 
management more effectively. Identifying women at risk 
for adverse outcomes would allow intensive monitoring 
or intervention and effective use of  resources; conversely, 
identifying women at low risk for these outcomes could 
decrease iatrogenic adverse maternal and neonatal outcomes 
by reducing unnecessary intervention and monitoring.
Routine clinical management of  women with preeclampsia 
often includes quantifying analytes of  hepatic function 
and integrity; these include aspartate amino transferase, 
alanine amino transferase, lactate dehydrogenase, bilirubin, 
albumin, and international normalized prothrombin 
time ratio. Previous studies have shown varying results 
for the ability of  liver function tests to predict adverse 
maternal outcomes. While some studies have found strong 
associations between levels of  AST, ALT, LDH, bilirubin, 
and adverse outcomes, others have found only weak 
associations or none at all. No consensus on reproducible 
predictive parameters has been reached.6–13 Some authors 
suggest that analytes such as LDH, bilirubin, and possibly 
AST may prove to be more predictive because they reect 
multiple organ dysfunction.9–12 The LDH level reects 
hemolytic cell damage and hepatic dysfunction, the bilirubin 
level reects both hemolysis and hepatic dysfunction, 
and the AST level reects tissue damage and hepatic 
dysfunction. The value of  changes to these liver function 
tests over time in predicting adverse maternal outcomes 
has yet to be assessed in women with preeclampsia.
In this study, we assessed the extent to which liver function 
tests can be used to predict adverse maternal outcomes 
in a large cohort of  women with preeclampsia. We also 
investigated whether the percentage change over time 
and the rate of  change of  each liver function test were 
predictive of  adverse maternal outcomes in this same well-
described cohort of  women with preeclampsia.
MATERIALS AND METHODS
The data used in this study were obtained from the 
PIERS. The PIERS study is a multicentre prospective 
cohort study examining predictors of  adverse maternal 
outcomes in women with preeclampsia. The PIERS 
cohort methodologies and multivariable results have been 
published elsewhere.5 Data from eligible women admitted 
to tertiary care centres were collected between September 
2003 and January 2010. The centres that participated 
were seven in Canada (British Columbia’s Women’s 
ABBREVIATIONS
ALT alanine amino transferase
AST aspartate amino transferase
AUC area under the curve
BP blood pressure
HELLP hemolysis elevated liver enzymes and low platelets
INR international normalized prothrombin time ratio
LDH lactate dehydrogenase
PIERS Pre-eclampsia Integrated Estimate of RiSK
ROC receiver operating characteristic
OCTOBER JOGC OCTOBRE 2011 l 997
Abnormal Liver Function Tests as Predictors of Adverse Maternal Outcomes in Women With Preeclampsia
Hospital, Vancouver, BC; Kingston General Hospital, 
Kingston, ON; Ottawa Hospital, Ottawa, ON; and Centre 
Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC), 
one in New Zealand (Christchurch Women’s Hospital in 
Christchurch), one in Australia (King Edward Memorial 
Hospital, Subiaco, Western Australia), and two in the 
United Kingdom (St. James Hospital, Leeds, Yorkshire and 
Nottingham University Hospital, Nottingham). In four of  
these sites, women were required to give informed consent 
to participate in the study. At the remaining sites, PIERS 
was conducted as a continuous quality improvement project 
that entailed the introduction of  predetermined guidelines 
for the initial assessment and ongoing surveillance of  
women admitted to hospital with a suspected or conrmed 
preeclampsia. The details of  these guidelines have been 
published elsewhere.14,15
Women were included in this study if  they met any of  the 
following criteria: (1) hypertension (BP ≥ 140/90 mmHg 
recorded on two occasions at least four hours apart, after 
20+0 weeks’ gestation, by any method in the hospital) 
and either proteinuria (urine protein ≥ 2+ by dipstick, 
≥ 0.3 g/day by 24-hour urine collection, or > 30 mg/mmol 
by spot urinary protein:creatinine ratio) or hyperuricemia 
(value greater than local upper limit of  normal for non-
pregnant individuals); (2) HELLP syndrome with or 
without hypertension; or (3) superimposed preeclampsia 
(pre-existing hypertension with any of  clinician-determined 
accelerated hypertension, systolic blood pressure 
≥ 170 mmHg, diastolic blood pressure ≥ 120 mmHg, new 
or accelerated proteinuria, or new hyperuricemia). Women 
were excluded from the study if  they were admitted to 
hospital in active labour or if  any element of  the combined 
adverse maternal outcome occurred prior to collection of  
predictor variables or prior to their meeting the eligibility 
criteria. This inclusive denition was chosen to reect the 
variable and multisystem nature of  preeclampsia seen in 
clinical practice.16–18
The PIERS database collected a wide range of  data pertaining 
to liver function (INR, serum albumin, unconjugated 
bilirubin) and cellular integrity (serum AST, ALT, LDH, 
total bilirubin) from all women who met eligibility criteria 
for the study. This information was collected on admission 
to hospital and at various times over the period of  hospital 
admission. All women who had baseline liver function 
tests performed after meeting eligibility criteria and at 
least one subsequent liver function test were included. The 
independent variables included for analysis in this study 
were levels of  AST, ALT, LDH, albumin, total bilirubin, 
and INR. The normal reference ranges at BC Women’s 
Hospital are AST: 10 to 40 U/L, ALT: 10 to 55 U/L, LDH: 
300 to 600 U/L, albumin: 37 to 56 g/L, total bilirubin: 
2 to 8 μM/L, and INR: 0.87 to 1.06. The normal reference 
ranges for all tests were similar between the institutions with 
the exception of  LDH, which differed between institutions 
depending on the particular laboratory test used by each 
site. To account for the discrepancy between the two LDH 
assays, results were corrected to the midpoint of  the relevant 
laboratory’s normal range. 5
The list of  adverse maternal outcomes for the PIERS study 
was developed by iterative Delphi consensus (members of  
the consensus are listed in the Acknowledgements).19,20 The 
combined maternal adverse outcome included maternal 
mortality and any of  the following maternal morbidities: 
hepatic dysfunction, hematoma, or rupture; one or 
more seizures of  eclampsia; Glasgow coma score < 13; 
stroke; reversible ischemic neurological decit; transient 
ischemic attack; posterior reversible encephalopathy; 
cortical blindness or retinal detachment; need for 
positive inotrope support; infusion of  a third parenteral 
antihypertensive; myocardial ischemia or infarction; acute 
renal insufciency; acute renal failure; dialysis; pulmonary 
edema; SpO2 < 90%; requirement of  ≥ 50% FiO2 for 
more than one hour; intubation (other than solely for 
Caesarean section); transfusion of  any blood product; 
severe thrombocytopenia (< 50 × 1012/L) in the absence of  
blood transfusion; and placental abruption. The combined 
perinatal adverse outcome comprised perinatal or infant 
mortality; bronchopulmonary dysplasia; necrotizing 
enterocolitis; grade III/IV intraventricular hemorrhage; 
cystic periventricular leukomalacia; and stages 3 to 5 
retinopathy of  prematurity.
Lead-time bias was addressed by standardizing eligibility 
from hospitalization with preeclampsia, and not necessarily 
from disease onset. Incompetence bias (missing values 
and misclassication) was reduced by abstractor training, 
development and validation of  the Microsoft Access 
database (Microsoft Corp., Redmond WA), feasibility and 
development studies using that database, and random re-
abstraction of  the charts. Misclassication errors were 
further minimized by database surveillance and 5% re-
abstraction. The study was pragmatic and, consistent 
with clinical care, test reproducibility was not examined; 
we relied on in-house training and review for ensuring 
test reproducibility. Customized case report forms and a 
Microsoft Access database were created for data entry and 
were used at all participating sites. Data were collected from 
the women’s medical records and included past obstetrical 
and family history, information regarding current pregnancy 
surveillance and outcomes, antenatal ultrasound ndings, 
laboratory testing, and delivery and neonatal outcomes.
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Women who had abnormal liver function test results 
were compared with women who had normal results. 
Descriptive data are expressed as median and interquartile 
range for non-normally distributed data. Fisher exact test 
was used for categorical variables, and Mann-Whitney 
U test was used for continuous variables. For each liver 
function test, we calculated the absolute test magnitude, 
percentage change of  test result within 48 hours of  
hospital admission, percentage change of  the test results 
from study eligibility to delivery or outcome, and rate of  
change from eligibility to delivery or outcome. Test results 
were grouped into quartiles, and the relationship between 
quartiles of  liver function test results and adverse maternal 
outcome was examined using logistic regression analysis. 
The lowest quartile of  liver function test results was 
used as the reference group for all tests except albumin 
(highest quartile was the reference group for albumin). 
Receiver operating characteristic curves were constructed 
for each liver function test to evaluate any potential value 
for predicting an adverse maternal outcome. Area under 
the curve of  ROC values > 0.7 were considered to be 
adequately predictive. P values < 0.05 were considered to be 
Table 1. Maternal and perinatal characteristics of women in the PIERS cohort with abnormal and normal 
liver function tests results
Abnormal liver function test(s) 
(N = 1056 women) 
(N = 1168 fetuses)
Normal liver function tests 
(N = 952 women) 
(N = 1035 fetuses) P*
Characteristic
Maternal age, years 31 (28 to 36) 31 (26 to 36) 003
Gestational age at eligibility, weeks 360 (326 to 383) 360 (332 to 381) 08
Gestational age at eligibility < 34 weeks 307 (281 to 326) 313 (287 to 329) 003
Multiple pregnancy 108 (102) 82 (86) 02
Parity ≥ 1 284 (266) 296 (311) 004
Smoking in current pregnancy 98 (99) n = 988 152 (166) n = 917 < 0001
Preeclampsia description < 0001
Hypertension and proteinuria 172 (163) 146 (153)
Hypertension and hyperuricaemia 696 (659) 635 (667)
HELLP without hypertension or proteinuria 52 (49) 0 (0)
Superimposed preeclampsia 135 (128) 171 (162)
Clinical
Peak blood pressure (mmHg)
Mean arterial pressure 1233 (1150 to 1303) 120 (1133 to 1267) < 0001
Systolic BP 166 (153 to 180) 160 (150 to 170) < 0001
Diastolic BP 103 (98 to 110) 100 (96 to 108) < 0001
Worst dipstick proteinuria 2 (1 to 3) 2 (05 to 3) < 0001
Lowest platelet concentration × 1012/L 172 (132 to 222) 214 (172 to 261) < 0001
Interventions
Corticosteroid administered 400 (379) 407 (428) 002
Antihypertensive medications administered 277 (262) 260 (273) 06
MgSO4 administered 458 (434) 227 (238) < 0001
Pregnancy outcomes
Admission-to-delivery interval in days 1 (1 to 3) 3 (1 to 11) < 0001
Gestational age at delivery in weeks 3643 (3329 to 3857) 3700 (3500 to 3857) < 0001
Birth weight in grams 2523 (1653 to 3178) 2685 (2000 to 3335) < 0001
Intrauterine fetal death 15 (13) 5 (05) 007
Neonatal death 11 (09) 9 (09) > 0990
Infant death 15 (13) 11 (11) 07
MgSO4: magnesium sulphate
Data are expressed as medians with interquartile ranges or percentages
*Fisher exact test (categorical variables) or Mann-Whitney U test (continuous)
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statistically signicant. Statistical analyses were performed 
using SPSS 18.0 (IBM Corp., Armonk NY).
Research Ethics Board approval was obtained at all sites.
RESULTS
Of the 2023 women entered into the PIERS database, 2008 
had at least one liver function test performed at the time of  
hospital admission and at least one subsequent liver function 
test. Of  these 2008 women, 1065 (53%) had at least one 
abnormal liver function test result. Demographic and clinical 
characteristics of  the women, and the pregnancy outcomes 
of  women with normal and abnormal test results, are shown 
in Table 1. There were no clinically signicant differences 
between the groups in maternal age, gestational age at eligibility, 
multiple pregnancy rates, or parity, despite some statistically 
signicant differences. Women with abnormal liver function 
test results had higher maximum systolic and diastolic blood 
pressures and a trend towards more proteinuria and lower 
platelet concentrations. Women with abnormal test results 
were more likely than others to use magnesium sulphate and 
corticosteroids. Women with abnormal liver function tests 
also had signicantly shorter admission to delivery intervals, 
lower gestational age at delivery, and infants with lower birth 
weights. Stillbirth was also more common in these women.
Maternal outcomes experienced by women with normal 
and abnormal test results are shown in Table 2. Women 
were grouped according to individual liver function test for 
analysis. Adverse maternal outcomes were more common 
in women with abnormal AST, ALT, LDH, total bilirubin, 
and INR results (P < 0.05). The specic maternal outcomes 
of  hepatic dysfunction or failure, hepatic rupture, and 
hepatic hematoma were more common in women who 
had abnormal ALT, total bilirubin, and INR results 
(P < 0.05).
Women with abnormal results were at higher risk than 
women with normal liver function tests results for adverse 
maternal outcomes (OR for AST 4.7 [95% CI 3.1 to 7.1]; 
for ALT 6.3 [95% CI 4.2 to 9.5]; for LDH 3.4 [95% CI 
1.9 to 5.8]; for albumin 1.2 [95% CI 0.4 to 3.9]; for total 
bilirubin 12.1 [95% CI 6.7 to 21.9]; and for INR 8.5 
[95% CI 4.5 to 15.9]). The association between quartiles 
of  liver function test results and risk of  adverse maternal 
outcomes is shown in Table 3. For all liver function tests, 
women in the highest quartile (lowest quartile for albumin) 
were at higher risk of  adverse maternal outcomes than 
women with laboratory results in the lowest quartile (highest 
quartile for albumin). Women in the second and third quartiles 
were not at signicantly increased risk of  adverse outcome, 
suggesting that the relationship between liver function test 
values and risk of  adverse outcome has a threshold effect 
rather than following a linear dose–response pattern. The 
odds ratios for percentage change within 48 hours were 
comparable to those for absolute test values. There were 
no signicant differences in the odds of  having an adverse 
outcome according to quartiles of  percentage change prior 
to adverse outcome or delivery and rate of  change.
Results of  the ROC AUC analysis for liver function tests 
predicting adverse maternal outcomes in women with 
preeclampsia are shown in Table 4. The worst laboratory 
result within 48 hours of  study eligibility was considered 
predictive of  adverse maternal outcome for AST 
Table 2. Adverse maternal outcomes within 48 hours of study eligibility in women with or without any abnormal  
liver function tests results. 
Test
AST 
n = 1937
ALT 
n = 2002
LDH 
n = 1616
Albumin 
n = 1741
Total bilirubin 
n = 1903
INR 
n = 1748
Test result Ab N Ab N Ab N Ab N Ab N Ab N
n 490 1447 228 1714 895 721 48 1693 56 1847 53 1695
% 253 747 144 856 554 446 28 972 29 971 30 970
All maternal outcomes
n 59 41 49 54 67 17 3 90 20 87 16 82
% 120 28 170 32 75 24 63 53 357 44 302 48
P < 0001 < 0001 < 0001 07 < 0001 < 0001
Hepato-specic maternal outcomes
n 4 3 5 5 5 2 0 9 4 6 3 6
% 08 02 17 02 06 03 0 05 71 03 57 04
P 007 0006 05 > 099 < 0001 0002
Ab: abnormal; N: normal
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Table 3. Risk of adverse maternal events according to quartile stratication of liver function test results by absolute 
magnitude of test result, percentage change of test result within 48 hours of hospital admission, percentage change of 
test result from admission to delivery/outcome, and rate of change of test result from admission to delivery/outcome 
Liver 
function 
test Parameter Quartile 1 Quartile 2 Quartile 3 Quartile 4
AST Absolute magnitude, U/L Range 
n/N 
OR (95% CI)
12 to 21 
13/515 
Reference
22 to 28 
9/468 
08 (03 to 18)
29 to 41 
19/484 
13 (08 to 32)
42 to 2475 
59/470 
55 (30 to 102)
Change within 48 hr of  
admission, %
Range 
n/N 
OR (95% CI)
−57 to 8 
6/275 
Reference
9 to19 
12/263 
21 (08 to 58)
20 to 41 
13/264 
23 (09 to 62)
45 to 5400 
28/255 
55 (23 to 136)
Change from admission to  
outcome/delivery, %
Range 
n/N 
OR (95% CI)
−81 to −10 
41/357 
Reference
−9 to 3 
36/343 
09 (06 to 15)
4 to 20 
40/349 
10 (06 to 16)
21 to 5400 
57/331 
16 (10 to 25)
Rate of change admission to 
outcome/delivery, unit/hr
Range 
n/N 
OR (95% CI)
−19 to −004 
44/355 
Reference
−003 to 0 
35/352 
08 (05 to 12)
001 to 010 
39/319 
10 (06 to 16)
011 to 100 
55/332 
14 (09 to 22)
ALT Absolute magnitude, U/L Range 
n/N 
OR (95% CI)
2 to 13 
13/569 
Reference
14 to 19 
10/434 
10 (04 to 23)
20 to 32 
19/510 
17 (08 to 34)
33 to 2020 
61/489 
61 (33 to 112)
Change within 48 hr of  
admission, %
Range 
n/N 
OR (95% CI)
−98 to 9 
14/274 
Reference
10 to 22 
12/266 
09 (04 to 19)
23 to 56 
9/271 
08 (04 to 18)
57 to 10 355 
29/267 
23 (12 to 44)
Change from admission to  
outcome/delivery, %
Range 
n/N 
OR (95% CI)
−99 to −15 
33/365 
Reference
−14 to 1 
43/361 
13 (08 to 21)
2 to 31 
46/358 
15 (09 to 24)
32 to 10 355 
61/361 
20 (13 to 32)
Rate of change admission to 
outcome/delivery, unit/hr
Range 
n/N 
OR (95% CI)
−256 to −004 
37/363 
Reference
−003 to 0 
38/378 
11 (07 to 17)
001 to 011 
47/337 
14 (09 to 23)
012 to 539 
58/346 
18 (11 to 28)
LDH Absolute magnitude, U/L Range 
n/N 
OR (95% CI)
038 to 113 
7/406 
Reference
114 to 135 
11/403 
16 (06 to 42)
136 to 170 
15/403 
22 (09 to 54)
171 to 1990 
51/404 
82 (37 to 184)
Change within 48 hr of  
admission, %
Range 
n/N 
OR (95% CI)
−39 to 8 
8/253 
Reference
9 to 22 
11/242 
15 (06 to 37)
23 to 49 
8/229 
11 (04 to 30)
50 to 1386 
27/241 
39 (17 to 87)
Change from admission to  
outcome/delivery, %
Range 
n/N 
OR (95% CI)
−83 to −11 
34/276 
Reference
−10 to 2 
25/264 
07 (04 to 13)
3 to 20 
26/275 
07 (04 to 13)
21 to 1248 
48/264 
16 (10 to 25)
Rate of change admission to 
outcome/delivery, unit/hr
Range 
n/N 
OR (95% CI)
−109 to −067 
46/299 
Reference
−066 to 007 
25/306 
05 (03 to 08)
008 to 158 
33/293 
07 (04 to 11)
159 to 600 
45/298 
10 (06 to 15)
Albumin Absolute magnitude, g/L Range 
n/N 
OR (95% CI)
11 to 26 
45/500 
25 (14 to 46)
27 to 29 
16/387 
11 (05 to 23)
30 to 32 
17/456 
10 (05 to 20)
33 to 40 
15/398 
Reference
Change within 48 hr of  
admission, %
Range 
n/N 
OR (95% CI)
−57 to −18 
28/248 
30 (14 to 64)
−17 to −10 
9/263 
08 (03 to 21)
−9 to −6 
7/248 
07 (02 to 19)
−5 to 23 
9/219 
Reference
Change from admission to  
outcome/delivery, %
Range 
n/N 
OR (95% CI) 
−36 to −10 
43/255 
18 (11 to 13)
−9 to −4 
32/251 
13 (08 to 22)
−3 to 0 
34/284 
12 (07 to 20)
1 to 45 
29/285 
Reference
Rate of change admission to 
outcome/delivery, unit/hr
Range 
n/N 
OR (95% CI)
−60 to −005 
38/262 
14 (09 to 24)
−004 to −009 
39/276 
14 (09 to 24)
−008 to 0003 
36/272 
13 (08 to 22)
0004 to 60 
27/256 
Reference
continued
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(0.73 [95% CI 0.67 to 0.79]), ALT (0.73 [95% CI 0.67 to 
0.79]), and LDH (0.74 [95% CI 0.68 to 0.81]). All other 
liver function tests had ROC AUC results < 0.7. Test result 
change within 48 hours of  study eligibility, change from 
study eligibility to delivery or outcome, and rate of  change 
from eligibility to delivery or outcome of  the test results 
were not predictive of  adverse maternal outcome for 
any liver function test. All ROC AUC results were < 0.7. 
A quadratic term to assess for a non-linear relationship 
between the liver function tests and adverse maternal 
outcomes was also included in the data analysis. This, 
however, did not improve the AUC of  the model.
DISCUSSION
This study used a large cohort to assess the value of  liver 
function tests to predict adverse maternal outcomes in 
women with preeclampsia. Abnormal liver function test 
results were found to be associated with a higher risk of  
adverse outcomes than normal results. We also found that 
within the range of  test results, women with results in the 
highest quartile (or lowest for albumin) had higher risk 
of  adverse outcomes than women with test results in the 
lowest quartile (or highest for albumin). Our results show 
that the levels of  ALT, AST, and LDH are all predictive 
of  adverse maternal outcomes in hospitalized women with 
preeclampsia. All three tests had an ROC AUC > 0.70. 
Change over time (from eligibility to delivery) and rate of  
change for each test all had ROC AUC < 0.7 and thus were 
not considered predictive of  adverse outcomes.
Strengths of  this study include the relatively large sample 
size of  women from multiple centres in several countries, 
ensuring that our cohort was heterogeneous in nature. 
Women with and without abnormal liver function test 
values were demographically similar, although there was 
more use of  magnesium sulphate and corticosteroids in 
women with abnormal test results than in women with 
normal results. This difference likely reects the fact that 
abnormal laboratory testing, including elevated levels of  
AST, ALT or LDH, is considered to be an adverse condition 
that is used to categorize preeclampsia as severe.2–4 Women 
with these results are therefore more likely to undergo 
interventions such as administration of  magnesium 
sulphate or corticosteroids or to have iatrogenic preterm 
delivery.
Table 3. continued
Liver 
function 
test Parameter Quartile 1 Quartile 2 Quartile 3 Quartile 4
Bilirubin Absolute magnitude, μM Range 
n/N 
OR (95% CI)
1 to 3 
8/240 
Reference
4 to 6 
24/813 
09 (04 to 20)
7 to 9 
22/483 
14 (06 to 32)
10 to 45 
47/367 
43 (20 to 92)
Change within 48 hr of  
admission, %
Range 
n/N 
OR (95% CI)
−83 to 20 
11/240 
Reference
21 to 33 
11/219 
11 (05 to 26)
34 to 61 
5/186 
06 (02 to 17)
62 to 900 
24/215 
26 (12 to 55)
Change from admission to  
outcome/delivery (%)
Range 
n/N 
OR (95% CI)
−83 to −1 
34/288 
Reference
0 to 14 
42/307 
07 (05 to 12)
15 to 50 
34/317 
07 (04 to 11)
51 to 3550 
47/353
09 (05 to 14)
Rate of change admission to 
outcome/delivery, unit/hr
Range 
n/N 
OR (95% CI)
−6 to 0 
79/536 
Reference
0001 to 0004 
12/87 
09 (06 to 14)
0005 to 005 
37/288 
08 (05 to 13)
006 to 60 
33/303 
07 (04 to 11)
INR Absolute magnitude Range 
n/N 
OR (95% CI)
070 to 090 
21/574 
Reference
091 to 092 
14/356 
11 (05 to 21)
093 to 094 
17/385 
12 (06 to 23)
095 to 131 
43/433 
29 (17 to 50)
Change within 48h of  
admission, %
Range 
n/N 
OR (95% CI)
−11 to 1 
9/255 
Reference
2 to 3 
8/104 
22 (08 to 59)
4 to 10 
15/115 
41 (17 to 97)
11 to 43 
19/136 
44 (19 to 101)
Change from admission to  
outcome/delivery, %
Range 
n/N 
OR (95% CI)
−25 to −1 
23/292 
Reference
−09 to 0 
43/518 
10 (06 to 17)
001 to 32 
10/145 
08 (04 to 18)
33 to 33 
25/149 
24 (13 to 43)
Rate of change admission to 
outcome/delivery, unit/hr
Range 
n/N 
OR (95% CI)
−015 to 
−000002 
35/269 
Reference
−000001 to 0 
25/288 
07 (04 to 12)
0 to 000003 
31/273 
08 (05 to 13)
000004 to 01 
50/265 
15 (09 to 24)
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Although absolute levels of  liver function test results were 
found to be associated with increased odds of  adverse 
maternal outcomes, their usefulness in a clinical setting 
may be limited. Serial monitoring is required to determine 
when test results reach a certain level. Women cannot be 
reassured that they are at low risk if  their levels are below 
a certain threshold because the possibility for an increase 
in risk exists as long as the pregnancy continues. However, 
normal liver function test results do provide some 
justication for expectant management, especially remote 
from term in women whose levels are (with the exception 
of  albumin) below the highest quartile values. Second, 
for the purposes of  our analysis no distinction was made 
between the various hypertensive disorders of  pregnancy. 
This may, however, be of  minimal signicance. A useful 
predictor of  the severity of  disease should be applicable 
to all such disorders, because it is often only in retrospect 
that we can determine precisely which disorder a woman 
was affected by. Last, although some of  the analyses in our 
study appear to be predictive, a proportion of  women who 
may go on to have severe disease will not be identied. A 
more robust model that takes into account the various end 
organ systems that can be affected by preeclampsia will 
likely yield a more clinically useful means for predicting 
disease severity. These ndings are consistent with those 
of  Martin et al. in a retrospective study of  970 patients 
with severe preeclampsia or HELLP.13 These authors 
found signicant differences in values on admission for 
ALT, AST, and LDH in women who experienced maternal 
morbidity versus women who did not. Both their study 
and ours examined women with severe preeclampsia with 
or without HELLP syndrome. Martin et al. proposed a 
protocol for early risk assessment of  severe preeclampsia 
that assessed symptoms and levels of  AST, ALT, LDH, uric 
acid, proteinuria, and creatinine, measured once shortly 
after meeting study admission criteria. They proposed that 
their ndings could be used as an adjunct to the Mississippi 
triple class system for categorizing and comparing patients 
with severe preeclampsia/HELLP.21 They suggested 
that regardless of  a woman’s initial or eventual HELLP 
Table 4. Predictive value of liver function tests to predict adverse 
maternal outcomes in women with preeclampsia 
Parameter Liver function test ROC AUC (95%CI)
Worst result in 48 hours of AST 073 (067 to 079)
study eligibility ALT 073 (067 to 079)
LDH 074 (068 to 081)
Albumin 063 (057 to 069)
Total bilirubin 068 (061 to 074)
INR 065 (058 to 071)
Test change within the rst 48 hours AST 066 (059 to 074)
of study eligibility ALT 062 (054 to 070)
LDH 065 (057 to 074)
Albumin 066 (057 to 075)
Total bilirubin 062 (053 to 071)
INR 067 (059 to 075)
Test change from eligibility to AST 055 (050 to 061)
outcome/delivery ALT 058 (053 to 062)
LDH 056 (050 to 061)
Albumin 056 (050 to 061)
Total bilirubin 050 (044 to 056)
INR 058 (051 to 065)
Rate of change from eligibility to AST 055 (050 to 059)
outcome or delivery (unit/hour) ALT 056 (052 to 061)
LDH 052 (047 to 058)
Albumin 054 (049 to 059)
Total bilirubin 047 (042 to 051)
INR 055 (049 to 060)
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classication, measurement of  LDH, ALT, and AST could 
be used to assess whether patients were at low, moderate, 
or high risk of  experiencing signicant maternal morbidity.
Peralta et al. described their ndings in 400 pregnant 
patients, of  whom 63 had mild preeclampsia, 153 had 
severe preeclampsia, and the remainder were healthy control 
subjects.22 In contrast to our ndings, these authors found 
no difference in levels of  AST, ALT, and total bilirubin 
between women with preeclampsia and normal control 
subjects. They did nd LDH levels to be signicantly 
different between the groups, and they concluded that 
LDH levels were useful in the diagnosis and classication 
of  severity of  preeclampsia, consistent with our ndings. 
The difference in results between the study of  Peralta et 
al.22 and our own may be due to differences in sample size 
and study patient populations. They compared women with 
preeclampsia with normotensive pregnant control subjects, 
whereas in our study only women who met criteria for 
having a hypertensive disorder of  pregnancy were included.
Von Dadelszen et al. retrospectively reviewed data from 
54 women with preeclampsia and found that AST levels 
were signicantly greater in women who had an adverse 
outcome than in those who did not.11 This study was much 
smaller than the current study, which may explain why only 
AST levels were identied as signicant.
Our results pertaining to the magnitude of  liver 
function test values may reect differences in end 
organ dysfunction at or near the time of  presentation. 
Preeclampsia is a systemic process characterized by 
increased systemic vascular resistance, increased platelet 
aggregation, abnormal coagulation, and endothelial 
dysfunction.23,24 The increased odds of  adverse maternal 
outcomes occurring in women in the highest quartiles 
(lowest for albumin) may be because they experience 
more severe effects of  the underlying disease process. 
Alternatively, women with more severely abnormal liver 
function tests could experience more adverse events as a 
result of  the physiologic derangements conferred by the 
systemic changes. For example, increased INR leads to 
increased risk of  hemorrhage, while low serum albumin 
will increase the risk of  pulmonary edema.
To our knowledge, no previous studies have assessed 
changes in liver function test values over time in relation 
to maternal outcomes. It is therefore unknown why the 
relationships seen in the rst 48 hours do not remain 
when a longer time period is analyzed, nor why rate of  
change is non-contributory. It may be that we were unable 
to account for rapid changes that occurred over short 
periods of  time. We compared only the initial and end 
point results of  each woman’s tests and the changes seen 
in test values may have accrued over only a portion of  the 
overall time period used to calculate the data. Thus our 
analysis would have missed these changes by averaging 
them over a longer time period. Future research that 
more meticulously examines the relationship of  change 
in liver values will be necessary to determine whether 
this is true. In assessing women with preeclampsia, liver 
function tests are only one set of  variables, and, although 
they do provide some insight into a woman’s disease 
status, a more robust multivariate model that takes into 
account the other organ systems affected by preeclampsia 
is needed. The recently published full PIERS model is 
such a multivariate model.5
CONCLUSION
This study has shown that a higher absolute magnitude 
of  liver function test results (or a lower serum albumin) is 
associated with increased occurrence of  adverse maternal 
outcomes. As well, percentage change in liver function 
test results within 48 hours appears to be associated with 
an increased occurrence of  adverse maternal outcomes. 
A clinically useful means for predicting disease severity 
based on change or rate of  change was not achieved by 
this study. However, as our knowledge of  the underlying 
pathophysiology of  the hypertensive disorders of  
pregnancy increases and further research in the area is 
undertaken, it is likely that the relationship between change 
or rate of  change in test results and maternal outcomes will 
be claried.
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